Table 1.
Experimental conditions of immunohistochemistry assays
| Antibody (clone) | Dilution | Source | Criteria for positive/negative |
|---|---|---|---|
| ER : Antibody (ID5) |
×100 |
Dako |
Positive: Stained cells >10% |
| PR : Antibody (PgR636) |
×500 |
Dako |
Positive: Stained cells >10% |
| HER2 (HercepTest) |
Ready to use |
Dako |
HercepTest criteria |
| EGFR (EGFR pharmDx kit) |
Ready to use |
Dako |
EGFR pharmDx kit criteria |
| CK5/6 (D5/16 B4) |
×100 |
Dako |
Positive: Stained cells >10% |
| PTEN (6H2.1) |
1:100 |
Dako |
- No staining |
| |
|
|
+ Decreased staining intensity |
| |
|
|
++ Equal or increased staining intensity |
| IGF-1R (C-20) |
1:50 |
Santa Cruz |
Score 0, 1+, 2+, 3+ using HercepTest criteria |
| Bcl-2 (124) |
×50 |
Dako |
Positive: Stained cells >10% |
| c-Kit (polyclonal; CD117) |
×500 |
Dako |
Positive: Stained cells >10% |
| c-Met (C-28, polyclonal) |
1:100 |
IBL |
Positive: Stained cells >10% |
| HIF-1α (H1alpha67) |
×100 |
Novus Biologicals |
Positive: Stained cells >10% |
| PDGFRA (C20, polyclonal) |
1:200 |
Thermo |
Positive: Stained cells >10% |
| Survivin (12C4) |
×200 |
Novus Biologicals |
Positive: Stained cells >20% |
| VEGFR2 (polyclonal; Flk-1(A-3)) |
×100 |
Santa Cruz |
Positive: Stained cells >10% |
| VEGF-A (VG1) | Ready to use | Thermo | Positive: Stained cells >10% |
ER: estrogen receptor, PR: progesterone receptor, HER2: human epidermal growth factor receptor type 2, EGFR: epidermal growth factor receptor, CK5/6: cytokeratin 5 or 6, PTEN: phosphatase and tensin homolog deleted on chromosome 10, IGF-1R: insulin-like growth factor-1 receptor, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor, HIF-1α: hypoxia-inducible factor 1-alpha, PDGFRA: alpha-type platelet-derived growth factor receptor, VEGFR2: vascular endothelial growth factor receptor 2, VEGF-A: vascular endothelial growth factor A.
NOTE. Dako: Tokyo, Japan. Santa Cruz: Tokyo, Japan. IBL: Gunma, Japan. Novus Biologicals: Littleton, Colorado, USA. Thermo: Waltham, Massachusetts, USA.